SEO URLwww.firestrike.ai/deals/ventyx-biosciences-lilly-acquisition-2026-4
acquisitionAnnounced · Jan 8, 2026PharmaceuticalsSource · CredibleArticle · Factual
Lilly acquires Ventyx Biosciences
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$1.2B
Target
Ventyx Biosciences
NASDAQ: VTYX · San Diego, California
Acquirer
Lilly
Full Acquisition
Status
Pending
Lilly agreed to acquire Ventyx Biosciences. Reported deal value: $1.2B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-08. Figures and status may change as filings and press coverage update.
Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in an all-cash transaction valued at approximately $1.2 billion to develop innovative oral therapies for patients with inflammatory-mediated diseases
Deal timeline
Announced
Jan 8, 2026 · pharmexec.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $1.2B. Figures and status may change as sources update.
Sources: pharmexec.com · Primary article · FireStrike proprietary index